

FOR IMMEDIATE RELEASE

Contacts:

Steve Parkinson
President and CEO
Lakewood-Amedex Inc.
(941) 359 0510 / 225 5859
sparkinson@lakewoodamedex.com

Paul DiTullio
Vice President
Lakewood-Amedex, Inc.
(941) 225-2516
pditullio@lakewoodamedex.com

LAKWOOD-AMEDEX RECEIVES NOTICE OF ALLOWANCE FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) FOR A NEW PATENT COVERING ITS nanoRNA GENE-SILENCING TECHNOLOGY

Sarasota, Florida, September 11, 2014 – Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent and Trademark Office has issued a ‘Notice of Allowance’ for patent application 11/673,486 entitled ‘Oligonucleotide-Containing Pharmacological Compositions And Their Uses’. The ‘486 patent application relates to the Company’s orally-deliverable nanoRNA therapeutics that act through gene-silencing and can be designed to treat a wide range of chronic and acute diseases such as arthritis, inflammation, influenza, hepatitis and many other viral indications. With this latest notice of allowance, the Company portfolio of patent in the antisense field expands to 36 on a worldwide basis with claims covering its proprietary chemistry, gene targets, and multiple indications.

Paul DiTullio, Vice President, Product Development remarked “The major advantages of the Company’s nanoRNA technology over other antisense, gene-silencing and RNAi technologies is a proprietary chemistry that overcomes the challenges of delivery. We have demonstrated in published studies that our compounds are highly effective when delivered intranasally against avian influenza and orally for the treatment of muscle wasting. This is a great advantage when treating chronic diseases such as inflammation, hepatitis, and cancer and also acute indications such as viral diseases. While our

main focus is on the Bisphosphocin™ family of broad spectrum antimicrobials about to enter human clinical trials due to the recent spike in viral outbreaks of Ebola and enterovirus we are now accelerating development of our lead nanoRNA therapeutic, Infl-uRNA, as a treatment for all influenza viral strains including H5N1 and H1N1. Our aim is to validate this platform technology for the rapid development of therapeutics to treat emerging viral diseases such as Ebola, SARS, and MERS, particularly given the current epidemics. This approach of rapidly shutting down viral replication may have significant advantages over vaccines that typically have limited product life and need to be given prior to infection.”

About Lakewood-Amedex, Inc.

Lakewood-Amedex is a privately held biopharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class anti-bacterial compounds, orally available nanoRNA therapeutics for acute and chronic diseases such as arthritis, inflammation, cancer, influenza, and hepatitis, and a fully human monoclonal antibody for HUS. The Company’s products and technology are covered by an extensive patent portfolio consisting of 74 granted and/or issued patents and 13 pending patent applications filed on a worldwide basis covering all major pharmaceutical markets. The Company’s lead therapeutic candidate is a novel synthetic broad spectrum anti-bacterial proven to be effective in killing a wide range of gram-positive, gram-negative, and antibiotic-resistant bacteria and is expected to enter the clinic in late 2014.

This press release contains forward-looking statements that can be identified by terminology such as "expects", "potential", "suggests", "may", "will" or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are "forward-looking statements" that involve risk and uncertainties, which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.